Anne J. Gonzales-Luna, research assistant professor in the Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, is reporting the weakening of ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

A new study published today in the American Journal of Infection Control (AJIC) describes the outcome of a new approach to testing for Clostridioides difficile (C. diff) guided by the principles of ...

There are inherent risks in biotech investing. A decade’s worth and often hundreds of millions of dollars in R&D, along with binary risks of failed clinical trials or regulatory approval. Above and ...

Current guidelines recommend using either metronidazole or vancomycin to treat C. diff infections. “For many years the two antibiotics were considered to be equivalent in their ability to cure C. diff ...

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C difficile Education & Advocacy, explained how FDA-approved microbiome-based therapeutics help to treat and ...

Spores of Clostridioides difficile are unaffected by treatment with bleach in the high concentrations commonly used for cleaning in many hospitals, a study found. Researchers from the University of ...

A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...

In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal ...